

Clinical Trial Protocol

Iranian Registry of Clinical Trials

27 Oct 2026

Evaluation the non-inferiority of filgrastim (zistdaru danesh) to neupogen (amgen) in the prevention of neutropenic complications in breast cancer patients: A phase III , randomized, triple-blinded (patient, outcome assessor and statistical analysis team), two armed clinical study.

Protocol summary

Study aim

Determining clinical efficacy of ZistDaru Danesh Company Filgrastim in preventing neutropenia versus Neupogen.

Design

A Phase 3, non-inferiority, two-arm, triple-blinded clinical trial study (patient, outcome assessor and statistical analysis team), parallel, active control. The randomization method is permuted block that consists of 4 blocks for total 208 patients.

Settings and conduct

Two groups of 104 patients will be randomly allocated to receive Filgrastim (ZDD company) and Neupogen 300 micrograms daily since 24 to 48 hours after the start of each chemotherapy cycle (each chemotherapy cycle is 14 days) for 5 days (up to a maximum of 10 days). Investigators, patients and evaluators will not be aware of the type of medicines.

Participants/Inclusion and exclusion criteria

Inclusion criteria: 1. Female gender age between 18 and 70 years with 40-100 kg. 2. Recognized with breast cancer treated with dose-dense AC regimen 3. ECOG score one and zero Exclusion criteria: 1. Existence of any serious systemic disorders associated with G-CSF incompatibility administration 2. Uncontrolled blood pressure history or other systemic disease 3. Heart failure regarding AC chemotherapy caution 4. Known severe coagulation disorder (hemophilia A or B) 5. Received any stem cell transplants 6. Any chemotherapy in the last five years 7. Receive doxorubicin or epirubicin 8. History of hypersensitivity to natural G-CSF or recombinant human albumin 9. Systemic or local infection or receive any antibiotic up to 10 days prior to study recruitment

Intervention groups

Granulocyte-colony stimulating factor (G-CSF) made by

zistdaru danesh company versus Neupogen as standard treatment.

Main outcome variables

The number of days that severe neutropenia occurs during the first chemotherapy cycle (Absolute Neutrophil Count < 500/microliter)

General information

Reason for update

Inclusion criteria changes according to proper dosage form and exclusion criteria based on caution to chemotherapy regimen

Acronym

IRCT registration information

IRCT registration number: **IRCT20211218053442N1**
Registration date: **2022-02-15, 1400/11/26**
Registration timing: **prospective**

Last update: **2023-09-18, 1402/06/27**

Update count: **2**

Registration date

2022-02-15, 1400/11/26

Registrant information

Name

Hooshmand Ilka

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 4231 8000

Email address

jahan.a@zistdaru.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-02-20, 1400/12/01

Expected recruitment end date

2024-02-20, 1402/12/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation the non-inferiority of filgrastim (zistdaru danesh) to neupogen (amgen) in the prevention of neutropenic complications in breast cancer patients: A phase III , randomized, triple-blinded (patient, outcome assessor and statistical analysis team), two armed clinical study.

Public title

Evaluation the non-inferiority of zistdaru danesh filgrastim to neupogen (amgen) in the prevention of neutropenic complications in breast cancer patients

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Female gender age between 18 and 70 years with weight range of 40-100 kg . Agree to participate in the study and sign an informed consent form. Recognized with breast cancer treated with doxorubicin hydrochloride (Adriamycin) and cyclophosphamide (AC) regimen Eastern Cooperative Oncology Group (ECOG) one and zero Candidate for preventive use for neutropenia (according to American society of clinical oncology (ASCO) guideline recommendation for prophylaxis of filgrastim in patients receiving chemotherapy regimens with more than 20% chance of developing neutropenia fever) Use at least one method of contraception from 4 weeks before the study until the end of the study Life expectancy more than 3 months Having the ability to receive treatment and follow-up Karnofsky performance status $\geq 70\%$ for patients ≤ 70 years of age and $\geq 90\%$ for patients > 70 years of age; adequate hematologic function (absolute neutrophil count [ANC] ≥ 3000 cells/ μL , platelet count $> 100,000/\mu\text{L}$, hemoglobin [Hb] ≥ 8 g/dL); adequate hepatic function (bilirubin $\leq 1.5 \times$ upper limit of normal [ULN], aspartate aminotransferase and alanine aminotransferase $\leq 2.5 \times$ ULN, alkaline phosphatase $\leq 5 \times$ ULN); creatinine $\leq 2.0 \times$ ULN; and normal cardiac function as determined by MUGA (multiple-gated acquisition) scan or echocardiography.

Exclusion criteria:

Existence of any serious systemic disorders associated with granulocyte-colony stimulating factor (GCSF) incompatibility administration Uncontrolled blood pressure history or other systemic disease Heart failure regarding AC chemotherapy intolerability Known severe coagulation disorder (hemophilia A or B) Participate in another clinical trial up to 30 days prior to drug administration Any chemotherapy in the last five years Receive doxorubicin > 600 mg/m² or Epirubicin > 240

mg/m² History of hypersensitivity to natural GCSF or recombinant human albumin Systemic or local infection or receive any antibiotic up to 10 days prior to study recruitment Receive concomitant radiotherapy or 4 weeks before enrollment Pregnancy

AgeFrom **18 years** old to **70 years** old**Gender**

Female

Phase

3

Groups that have been masked

- Participant
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample sizeTarget sample size: **208****Randomization (investigator's opinion)**

Randomized

Randomization description

Build numerical sequences: Patient randomization program is done by an online system (<http://www.sealedenvelope.com>). The randomization method in this system is permuted block randomization. The length of each block includes 4 patients, which will be made for a total of 208 patients. When randomization is performed, each patient receives a code that will be recognized by the study. The code will consist of two numbers (according to the randomization number) and four letters (according to the first two letters of the name. The first two letters of the surname). Randomization numbers are determined sequentially. In each center, after examining the inclusion and non-inclusion criteria of patients, with a pre-determined telephone (clinical study partner in Tehran, whose specific task in the whole study is only to coordinate with researchers).) Will be called and given a randomization code (written on the drug label in the stock of each site). Determining the group of patients (concealment process) A random chain is created and anonymous codes corresponding to each patient (generated by the online software) are pasted on the drug labels and prepared in advance at the patient's sites. After the patient enters the study, only the desired code will be announced on the site and the corresponding drug will be prescribed to the patient.

Blinding (investigator's opinion)

Triple blinded

Blinding description

Blinding process: This study is performed in a triple-blind manner. All staff involved in the study, patients and statistical analysis team are unaware that the person receiving the zistdaru danesh filgrastim under study or the neupogen. Filgrastim and AMGEN Neupogen are sent to centers in their original packaging. In each center, 1 unblinded person is responsible for the preparation (change of drug labels) based on the random code assigned to the patient, and each drug will be given to

the person responsible for injection (blinded nurse) after preparation in the same package. For this reason, the group involved in the patient's treatment process and evaluating the results of the study will be completely different from the personnel involved in the preparation of the drug. The randomized table will remain strictly confidential with the randomization center and will not be provided except in legal cases.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Tehran University of Medical Sciences

Street address

Vice-Chancellor in Research Affairs-Tehran University of Medical Science, 6th floor, near Qods st, keshavarz blvd.

City

Tehran

Province

Tehran

Postal code

1417613151

Approval date

2021-10-18, 1400/07/26

Ethics committee reference number

IR.TUMS.TIPS.REC.1400.155

Health conditions studied**1****Description of health condition studied**

Neutropenia

ICD-10 code

D70

ICD-10 code description

Neutropenia

Primary outcomes**1****Description**

The number of Days that severe neutropenia occurs during the first chemotherapy cycle according to absolute neutrophil count < 500 per microliter of blood

Timepoint

The first chemotherapy cycle

Method of measurement

Absolute number of blood neutrophils in terms of number per microliter of blood

Secondary outcomes**1****Description**

Occurance of febrile neutropenia

Timepoint

The start of medication in both groups until the last visit

Method of measurement

Fever over 38.5 centigrade degree for at least 1 hour and neutropenia less than 500 per microlitr blood coincidence.

2**Description**

Incidence of neutropenia defined as absolute neutrophil count < 0.5 x 10e9/L not associated with fever

Timepoint

The start of medication in both groups until the last visit

Method of measurement

Absolute neutrophil count per microliter of blood and fever measurement with thermometer (temperature more than 38 degree of centigrade) .

3**Description**

Determine the exact count of neutrophils

Timepoint

The start of medication administration in both groups until the last visit

Method of measurement

Absolute neutrophil count per each microliter of blood

4**Description**

Incidence of infections

Timepoint

The start of medication in both groups until the last visit

Method of measurement

According to blood, respiratory secretion or urine culture

5**Description**

Incidence of need for IV anti-infectives

Timepoint

The start of medication in both groups until the last visit

Method of measurement

According to the results of the culture or clinical symptoms

6**Description**

As a result of neutropenia Incidence of hospitalization

Timepoint

The start of medication in both groups until the last visit

Method of measurement

Patient history taking

7

Description

As a result of neutropenia ,Duration of hospitalization

Timepoint

The start of medication in both groups until the last visit

Method of measurement

Patient visit

8

Description

Ability to maintain planned chemotherapy dose on time for cycles 2 to 6

Timepoint

every chemotherapy cycle

Method of measurement

Patient visit

9

Description

Cumulative r-G-CSF dose

Timepoint

The start of medication in both groups until the last visit

Method of measurement

The number of filgrastim during the study period

Intervention groups

1

Description

Invention group : Administration of Filgrastim ZistDaru at a dose of 300 mcg, 24-48 hours after the first cycle of chemotherapy until ANC more than 5×10^9 and maximum for 10 days (each one occurred earlier)

Category

Treatment - Drugs

2

Description

Control group: group Administration of Neupogen (Filgrastim AMGEN company) at a dose of 300 mcg, 24-48 hours after the first cycle of chemotherapy until ANC more than 5×10^9 and maximum for 10 days (each one occurred earlier)

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Laleh hospital

Full name of responsible person

Seyed mohamadreza mortazavi zahdeh

Street address

Laleh hospital, Simaye-Iran Ave., Phase 5, Shahrak-e Gharb

City

Tehran

Province

Tehran

Postal code

1467684595

Phone

+98 21 8896 3546

Email

Mortazavizadeh@yahoo.com

2

Recruitment center

Name of recruitment center

Emam-Hosseini hospital

Full name of responsible person

Ali Yaqoubi Jooybari

Street address

Emam-Hosseini hospital, Shahid-Madani Ave., Tehran

City

Tehran

Province

Tehran

Postal code

1617763141

Phone

+98 21 8896 3546

Email

samieifarhad@yahoo.com

3

Recruitment center

Name of recruitment center

Seyed-o Shohada hospital

Full name of responsible person

Mohammad Taheri

Street address

Seyed-o Shohada hospital, Khayam Ave., Isfahan

City

Isfahan

Province

Isfahan

Postal code

8379181331

Phone

+98 31 3235 0212

Email

samieifarhad@yahoo.com

4

Recruitment center

Name of recruitment center

Shahid-Madani hospital

Full name of responsible person

Alireza Naseri

Street address

Shahid Madani Hospital, Daneshgah Ave., Tabriz
City
Tabriz
Province
East Azarbaijan
Postal code
5133151999
Phone
+98 41 3334 7054
Email
samieifarhad@yahoo.com

5

Recruitment center

Name of recruitment center
Imam-Khomeini hospital
Full name of responsible person
Farhad Samiei
Street address
Cancer Institute, Imam Khomeini Hospital Complex,
End of Keshavarz Blvd., Tehran, Iran.
City
Tehran
Province
Tehran
Postal code
1419733141
Phone
+98 21 8896 3546
Email
samieifarhad@yahoo.com

6

Recruitment center

Name of recruitment center
Dr. Mortazavizadeh Clinic
Full name of responsible person
Seyed mohamadreza mortazavi zahdeh
Street address
No. 25, Shahid Haj Mohammadi Alley, Taleghani Blvd.,
Azadi Square, Yazd
City
yazd
Province
Yazd
Postal code
8915635796
Phone
+98 35 3725 0044
Email
Mortazavizadeh@yahoo.com

7

Recruitment center

Name of recruitment center
Dr. Syed Mohsen Razavi's office
Full name of responsible person
Seyed Mohsen Razavi
Street address
2nd floor, No. 482, in front of Tehran Hotel, Motahari

St., Valiasr St., Tehran
City
Tehran
Province
Tehran
Postal code
1593748711
Phone
+98 21 6646 7901
Email
rsmrazavi@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Zistdaru Danesh Co. ®
Full name of responsible person
Hooshmand Ilka
Street address
First floor, No. 33, Ebn-e Yamin Ave., North
Sohrevardi Ave., Tehran
City
Tehran
Province
Tehran
Postal code
1555633114
Phone
+98 21 4231 8101
Fax
+98 21 4231 8123
Email
info@zistdaru.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Zistdaru Danesh Co. ®

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Industry

Person responsible for general inquiries

Contact

Name of organization / entity
Pharmed Pajoohan Viera
Full name of responsible person
Maryam Azimi

Position

Medical department manager

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Unit 2, No. 14., 16th Gandhi Ave., Valiasr street,
Tehran

City

Tehran

Province

Tehran

Postal code

1517854313

Phone

+98 21 8866 0795

Fax

+98 21 8866 0795

Email

info@ppvcro.com

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Farhad Samiei

Position

Assistant Professor

Latest degree

Subspecialist

Other areas of specialty/work

Oncology

Street address

Cancer Institute, Emam-Khomeini hospital, Keshavarz
Blvd., Tehran

City

tehran

Province

Tehran

Postal code

1419733141

Phone

+98 21 8896 3546

Email

samieifarhad@yahoo.com

Person responsible for updating data

Contact**Name of organization / entity**

Mazandaran University of Medical Sciences

Full name of responsible person

Monireh Ghazaeian

Position

Assistant professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Farahabd street, Khazar Blvd, Mazandaran University
Medical Sciences Complex.

City

Sari

Province

Mazandaran

Postal code

4815733971

Phone

+98 11 3354 2472

Fax

+98 21 8896 3546

Email

ghazaeianm@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

No more information.

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available